Scroll
To Top
0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

*Important

The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.


LGMD2I Research Fund


Address

PO Box 245
Bellevue, WA 98009

Phone

4254602554

Fax

4254601236

Email Address

jpl@lgmd2ifund.org

Description

LGMD2I Research Fund is a non-profit 501(c)3 organization whose mission is to expedite the development of a treatment and/or cure for limb girdle muscular dystrophy 2I (LGMD2I). To achieve this goal, they are building a comprehensive view of the entire LGMD2I research landscape, placing well-informed bets on where the most promising research is being done, and bringing a level of coordination and management to the scientific process. Limb-girdle muscular dystrophies (LGMD) are a group of rare progressive genetic disorders that are characterized by wasting (atrophy) and weakness of the voluntary muscles of the hip and shoulder areas (limb-girdle area). Muscle weakness and atrophy are progressive and may spread to affect other muscles of the body. Many different subtypes have been identified based upon abnormal changes (mutations) of certain genes. The various forms of LGMD may be inherited as autosomal dominant or recessive traits. Autosomal recessive LGMD is known as LGMD2 and has 17 subtypes (LGMDA-Q).

Please Note

The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.

NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.